PARP inhibitors are a promising alternative to chemotherapy for patients with metastatic BRCA1 and BRCA2 breast cancer

MONALEESA-7: Results from phase III trial looking at ribociclib as an addition to endocrine therapy in advanced breast cancer

Subcutaneous versus intravenous daratumumab administration in patients with relapsed or refractory multiple myeloma

KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as treatment for aNSCLC

KEYNOTE-062 study: Pembrolizumab as treatment for advanced gastroesophageal junction and gastric cancers

Comment: Reasonable to conclude that pembrolizumab is non-inferior to chemotherapy

Pembrolizumab comparable to chemotherapy for patients with advanced gastric or gastroesophageal junction cancers

Comment: The success of immunotherapy means we have to change our mindset as we treat patients

Pembrolizumab is safe and effective and substantially increases overall survival in aNSCLC patients

Comment: The use of CDK 4/6 inhibitors now translates to a significant survival benefit in breast cancer treatment

Ribociclib and endocrine therapy improves survival for pre-menopausal women with advanced breast cancer

Highlights from SIOP Africa 2019